<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17181" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Drug Addiction</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fluyau</surname>
            <given-names>Dimy</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Charlton</surname>
            <given-names>Thomas E.</given-names>
          </name>
          <aff>Central Michigan University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dimy Fluyau declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Charlton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17181.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The definition of addiction among the general population is a fact or condition of being addicted to a particular substance, thing, or activity. Medically,&#x000a0;there are&#x000a0;2 categories: substance&#x000a0;and nonsubstance addiction, and many risk factors predispose individuals to both. In particular, a history of risk-taking behavior, genetic predisposition, and propensity for stress play a role. Over time, addiction changes parts of the brain, specifically the dopaminergic system, responsible for perceiving rewards.</p>
        <p>Addiction is a chronic, relapsing brain disease that leads to medical, psychological, and social complications. This activity outlines the importance of the interprofessional team in&#x000a0;treating patients with addiction to ensure the best long-term outcomes. Participating clinicians review the importance of considering a holistic approach to the care of their patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;the&#x000a0;relationship between genetics and addictive behaviors.</p></list-item><list-item><p>Evaluate&#x000a0;the presentation of a patient with&#x000a0;the most common types of&#x000a0;addiction.</p></list-item><list-item><p>Interpret&#x000a0;the toxicokinetics of alcohol intoxication as the most common intoxication.</p></list-item><list-item><p>Explain the importance of care coordination among the interprofessional team to deliver optimal care for patients with addiction.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17181&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17181">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17181.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The definition of addiction among the general population is "the condition of being addicted to a particular substance, thing, or activity." Medically, it may be defined as "a chronic, relapsing condition characterized by a compulsive drug-seeking behavior, continued use despite harmful consequence, and long-lasting changes in the brain." This current Oxford English dictionary definition&#x000a0;is traced back to Roman law in which addiction was a "formal giving over by sentence of the court."<xref ref-type="bibr" rid="article-17181.r1">[1]</xref>&#x000a0;The concept&#x000a0;relates to&#x000a0;the relinquishment of control by the "addicted" person, identical to how drug-dependent patients succumb to the cravings for their drug of choice.</p>
        <p>Two main concepts of addiction involve substance addiction (drug addiction), a neuropsychiatric disorder characterized by a repeated desire to take a drug continuously despite the drug's harmful consequences. Nonsubstance addiction (behavioral addiction) does not involve&#x000a0;a drug. Still, it includes similar behaviors as when one uses a drug, such as pathological gambling, food addiction, internet addiction, gaming, sex addiction, and mobile phone addiction.<xref ref-type="bibr" rid="article-17181.r2">[2]</xref></p>
      </sec>
      <sec id="article-17181.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>A complex interplay of neurobiology, genetics, and the environment accounts for the development of addiction, alcohol, and other drug use disorders. Reward activity is a piece of available evidence that supports the neurobiological underpinnings of addiction. However, observations implicating the dopamine reward system may downplay the potential contribution of learning and memory in the hippocampus and emotional regulation in the amygdala as possible etiologies in developing and maintaining an addiction.<xref ref-type="bibr" rid="article-17181.r3">[3]</xref><xref ref-type="bibr" rid="article-17181.r4">[4]</xref><xref ref-type="bibr" rid="article-17181.r5">[5]</xref></p>
        <p>The implication of genetics across addictive behaviors was suggested via the transcription factor Delta-FosB. Delta-FosB&#x000a0;is among the mechanisms by which the abuse of drugs can produce changes in the brain and contribute to the addiction phenotype. Delta-FosB, a member of the Fos family of transcription factors, accumulates within a subset of neurons of the nucleus accumbens and dorsal striatum after multiple administrations of illicit drugs. Studies also found a similar accumulation of Delta-FosB in the brain after compulsive running, suggesting that Delta-FosB may accrue in many types of compulsive behaviors.<xref ref-type="bibr" rid="article-17181.r6">[6]</xref><xref ref-type="bibr" rid="article-17181.r7">[7]</xref></p>
        <p>Furthermore, how individuals handle stress psychologically, physically, and biochemically plays a significant role in the context of parental use, psychological or cognitive deficits, and levels of stress.<xref ref-type="bibr" rid="article-17181.r1">[1]</xref></p>
        <p>Preclinical research has shown that stress exposures, especially in early life with child maltreatment and regular adversity, enhance drug self-administration and precipitate many relapses in individuals with addiction. Specifically, there are notable changes in the corticotropin-releasing factor, the hypothalamic-pituitary-adrenal axis (CRF/HPA), and autonomic arousal.<xref ref-type="bibr" rid="article-17181.r8">[8]</xref> In essence, stress refers to processes that involve perception, appraisal, and response to harmful, threatening, or challenging events or stimuli.<xref ref-type="bibr" rid="article-17181.r8">[8]</xref> Stress can be helpful, and persevering through stress results in feelings of mastery and accomplishment. However, any 'stress' that&#x000a0;is prolonged or chronic can become unpredictable and uncontrollable, resulting in a loss of sense of accomplishment or adaptability and the development of homeostatic dysregulation. This homeostatic dysregulation creates the potential for drug-seeking behaviors and possibly addiction.</p>
        <p>Studies in Latin American laboratories highlight the association between single nucleotide polymorphisms (SNPs) in stress-related genes and addiction. SNPs may interact with stress hormones, transcription factors, and cytokines. This interaction may be a pathway to identify reliable biomarkers of vulnerability to drug abuse and relapse. Other studies also suggest that CRF receptors in the lateral septum and the&#x000a0;ventral tegmental area (VTA), specifically the CRF2-alpha-R isoform, are a potential therapeutic target for drug addiction. The Wnt family of secreted glycolipoproteins and their interplay could explain the interaction between stress and addictive behavior. Researchers also studied the cannabinoid system as a promising target for stress-induced relapse on drugs.<xref ref-type="bibr" rid="article-17181.r9">[9]</xref></p>
        <p>In summary, addiction consistently finds roots in stressful contexts, particularly when prolonged throughout early childhood. Environmental risk factors such as impulsivity, inadequate parental supervision, and delinquency are common across chemical and behavioral expressions of addiction. Studies suggest that individuals who engage in one problem behavior are likely to engage in another problem behavior. Sociodemographic risk factors related to poverty, geography, family, and peer groups also influence the onset and course of substance and non-substance addiction.</p>
      </sec>
      <sec id="article-17181.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>A study in 2005, reflecting on the 2001 National Household Survey of Drug Abuse, found that out of 55561 subjects, 33576 reported alcohol use within the past year. Ultimately, the study found a slightly higher prevalence of abuse-to-dependence in males&#x000a0;and&#x000a0;females with (2.1 to 1) and (1.6 to 1).<xref ref-type="bibr" rid="article-17181.r10">[10]</xref>&#x000a0;Per a research study in 2014, 7% of the American population meets the criteria for the diagnosis of alcohol misuse or alcoholism.<xref ref-type="bibr" rid="article-17181.r10">[10]</xref> In 2010, the World Health Organization (WHO) estimated about 208 million people worldwide&#x000a0;have alcohol use disorder. In 2016, globally, alcohol dependence was the most prevalent substance use disorder, but the most common drug use disorders in 2016 were cannabis and opioids. Amphetamine and cocaine use was less frequent.<xref ref-type="bibr" rid="article-17181.r11">[11]</xref></p>
        <p>Designer drugs are illicitly produced chemical analogs to preexisting psychoactive or analgesic molecules. These drugs&#x000a0;are more potent than known controlled or uncontrolled substances. There is a growing international concern that designer drugs are manufactured and distributed to circumvent drug laws and evade interdiction.<xref ref-type="bibr" rid="article-17181.r12">[12]</xref> Designer drugs keep changing depending on the location. Among them are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Synthetic stimulants like bath salts, a synthetic cathinone</p>
          </list-item>
          <list-item>
            <p>A synthetic version of tetrahydrocannabinol (THC) called k2 or spice</p>
          </list-item>
          <list-item>
            <p>A norepinephrine-dopamine reuptake inhibitor and a member of the cathinone and pyrovalerone classes called flakka</p>
          </list-item>
          <list-item>
            <p>Synthetic designer hallucinogens called N-bomb and solaris<xref ref-type="bibr" rid="article-17181.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Synthetic opioid-non-fentanyl derived ones, such as U-47700, called "U4," "pink," or "pinky, U-49900, AH-7921, or MT-45<xref ref-type="bibr" rid="article-17181.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Methylenedioxy-derivatives of amphetamine and methamphetamine</p>
          </list-item>
        </list>
        <p>The most used chemical is 3,4-methylenedioxymethamphetamine (MDMA-ecstasy).<xref ref-type="bibr" rid="article-17181.r14">[14]</xref>&#x000a0;The use of designer drugs is mostly encountered among young males who are 15 to 25 years old and who frequent clubs, raves, and house parties. In 1993, the National Institute on Drug Abuse survey reported an estimate of 2% of all American college students&#x000a0;admitted to using MDMA in the previous 12 months.<xref ref-type="bibr" rid="article-17181.r12">[12]</xref>&#x000a0;Several studies estimated that 6% to 17% of American college students had used synthetic cannabinoid drugs at least once.<xref ref-type="bibr" rid="article-17181.r15">[15]</xref> Around 1% of young Europeans between the ages of 14 and 18 used synthetic cannabinoid drugs at least once in their lifetime.<xref ref-type="bibr" rid="article-17181.r16">[16]</xref></p>
        <p>Deaths by overdose were increased by adulterants in products sold as heroin or as counterfeit painkillers in North America and Canada. In a city like Miami, there was an increase of 600% in fentanyl-related deaths reported from 2014 to 2015. Fatalities from these novel synthetic opioids were also reported in North America, Latin America, Canada, Asia, Europe, and Africa.<xref ref-type="bibr" rid="article-17181.r17">[17]</xref><xref ref-type="bibr" rid="article-17181.r18">[18]</xref></p>
        <p>Abuse of prescription medicines involves:</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous depressants (benzodiazepines, non-benzodiazepines, and barbiturates).</p>
          </list-item>
          <list-item>
            <p>Prescription opioids (hydrocodone, oxycodone, fentanyl, and codeine).</p>
          </list-item>
          <list-item>
            <p>Prescription stimulants (dextroamphetamine, dextroamphetamine or amphetamine combination product, and methylphenidate).</p>
          </list-item>
        </list>
        <p>Deaths from prescription opioid overdose were&#x000a0;5 times higher in 2016 than in 1999. In 2012, the National Center for Health Statistics reported that pain relievers (opioids) were involved in more "drug poisoning deaths" than heroin and cocaine.<xref ref-type="bibr" rid="article-17181.r19">[19]</xref></p>
        <p>Around 9.7% of students in grades 7 to 12 reported using dextromethorphan recreationally in 2013, compared with 6.9% in 2011, based on the Ontario Student Drug Use and Health Survey. Most of the calls to poison control were related to dextromethorphan, which involved adolescent males.<xref ref-type="bibr" rid="article-17181.r19">[19]</xref>&#x000a0;Acetylsalicylic acid (ASA) or acetaminophen use of more than 4 g per day for an extended time is considered misuse.<xref ref-type="bibr" rid="article-17181.r20">[20]</xref></p>
        <p>Extracts of many leaves&#x000a0;have been found to possess a powerfully addictive substance. One such example is an extract from the&#x000a0;<italic toggle="yes">Mitragyna speciosa</italic> (kratom) tree. Kratom is the subject of attention worldwide<italic toggle="yes">.</italic>&#x000a0;Reports suggest that calls to poison centers related to kratom use, by year, increased from 2010 to 2015. Kratom (<italic toggle="yes">M speciosa</italic>) misuse appears to be rising in the Western world at an alarming rate, with reported deaths.<xref ref-type="bibr" rid="article-17181.r21">[21]</xref></p>
      </sec>
      <sec id="article-17181.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of addiction revolves around the concepts of synaptic plasticity, specifically&#x000a0;long-term potentiation (LTP) and&#x000a0;long-term depression (LTD). Long-term potentiation is the phenomenon of strengthened neural connections over time and with increased stimuli. Long-term depression is the decrease in the responsiveness of a neural signal with stimulation. These are the same processes involved in learning and habit formation. The biochemical proof in drug addiction is founded in the same molecules undergoing upregulation in both cases&#x02014;extracellular signal-regulated protein kinase (ERK), cyclic AMP response element-binding (CREB), ELK-1, and Fos.<xref ref-type="bibr" rid="article-17181.r22">[22]</xref>&#x000a0;Rats treated to suppress ERK stopped preferring the caged area with cocaine over the caged area with normal saline.<xref ref-type="bibr" rid="article-17181.r22">[22]</xref>&#x000a0;Eventually, CREB, ELK-1, and Fos decreased, each known to be involved with LTP and drug misuse.<xref ref-type="bibr" rid="article-17181.r22">[22]</xref></p>
        <p>Biochemical studies have shown the involvement of a dynorphin A (DYN) and K-opioid receptor (KOPr) system.<xref ref-type="bibr" rid="article-17181.r23">[23]</xref> This system is found throughout the brain and spinal cord. Specifically, KOPr is found within brain circuits that regulate mood and motivation through dopaminergic and glutamatergic neurotransmitters. Studies have shown that dysregulation in this system has led to not only the anhedonia and depressive symptomatology of withdrawal but also drug-craving and drug-seeking behaviors.<xref ref-type="bibr" rid="article-17181.r23">[23]</xref>&#x000a0;These 2 systems are involved&#x000a0;in addiction development. Further research continues&#x000a0;to study the process of addiction.</p>
        <p>Furthermore, research indicates that dopamine is a critical player in terms of neurological changes in the brain of an individual with addiction. A quick&#x000a0;and significant rise is&#x000a0;associated with the onset and maintenance of an addiction.<xref ref-type="bibr" rid="article-17181.r24">[24]</xref>&#x000a0;As the habit becomes chronic, dopamine decreases and eventually changes the prefrontal region of the brain, specifically the orbitofrontal cortex and cingulate gyrus.<xref ref-type="bibr" rid="article-17181.r24">[24]</xref></p>
      </sec>
      <sec id="article-17181.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Being the most common and costly intoxication, it is essential to review the toxicokinetics of alcohol intoxication. Upon intake, alcohol begins metabolism with extensive first-pass metabolism catalyzed by the enzyme alcohol dehydrogenase (ADH).<xref ref-type="bibr" rid="article-17181.r25">[25]</xref> While all the cells in our body can metabolize alcohol, most occur in the liver with ADH and CYP2E1 (though CYP450 enzymes&#x000a0;are inactive until reaching chronic abuse or ingesting substantial amounts). Ethanol is metabolized initially to acetaldehyde, which gets further metabolized in mitochondria to acetate via acetaldehyde dehydrogenase. While acetate enters the peripheral circulation for utilization in various reactions as the key intermediate acetyl CoA, acetaldehyde forms in addicts, causing injury by activating immune processes.</p>
        <p>This reaction finds particular relevance in alcoholic liver disease as ADH and ALDH1 reduce all stores of NAD+ to NADH. The eventual damage is the result of reactive oxygen species (ROS). Typically, glutathione (GSH) stores neutralize ROS, but alcohol depletes GSH stores, leaving ROS unchecked. For example, ROS interacts with lipids to undergo lipid peroxidation, resulting in malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE), which can form protein adducts.<xref ref-type="bibr" rid="article-17181.r25">[25]</xref> Thus, alcohol metabolism, specifically through the generation of ROS and depletion of reducing agents such as GSH, causes damage to multiple organs in the body, such as the liver, lungs, muscles, and brain.<xref ref-type="bibr" rid="article-17181.r25">[25]</xref></p>
        <p>For reference, the average rate of alcohol metabolism is 7 g/h or roughly one drink/h.</p>
      </sec>
      <sec id="article-17181.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History and physical examination of individuals with addiction vary depending on the type of addiction, substance ingested, time since ingestion, and route. For example, most forms of alcohol intoxication present with slurred speech, ataxia, and impaired judgment. Depending on the dose and time frame of ingestion, this process can quickly spiral toward CNS depression, coma, and multiorgan failure. This progression applies to ethanol, methanol, isopropanol, and ethylene glycol.</p>
        <p>Regarding cocaine and other stimulants, expect an acute patient with anxiety, potential psychosis, and sympathetically-driven vital signs (tachycardia, tachypnea, high blood pressure, etc).<xref ref-type="bibr" rid="article-17181.r26">[26]</xref> Management begins with decreasing stress, stabilizing vitals, and preparing rapid response teams for deteriorating patients.</p>
        <p>Also, significant variations are based on the stage of addiction and addictive substances.</p>
        <p>The&#x000a0;5 stages of addiction are as follows:</p>
        <list list-type="order">
          <list-item>
            <p><bold>First Use:&#x000a0;</bold>These are na&#x000ef;ve patients because they have not yet felt the effects of their substance. It could be a new pain medication prescription or peer-pressure-imposed experimentation.</p>
          </list-item>
          <list-item>
            <p><bold>Continued Use:&#x000a0;</bold>Individuals begin to return to a medication they no longer &#x0201c;need&#x0201d; but want as they notice the post-high sensation does not clear as quickly.</p>
          </list-item>
          <list-item>
            <p><bold>Tolerance:&#x000a0;</bold>Patients in this stage realize they need large doses of the drug to feel prior levels of high.</p>
          </list-item>
          <list-item>
            <p><bold>Dependence:&#x000a0;</bold>Patients begin to show physical signs of withdrawal from discontinuing use. In addition, patients do not feel &#x0201c;normal&#x0201d; without their substance.</p>
          </list-item>
          <list-item>
            <p><bold>Addiction:&#x000a0;</bold>These patients can be on one of&#x000a0;2 sides of the coin. They may be distressed by continued use but require it despite serious life problems that have resulted, or they may be in denial of the addiction and continue to spiral further.</p>
          </list-item>
        </list>
        <p>The above descriptions of stages reveal the expected presentation of the addicted patient. History and physical examination will vary based on the stage of the condition. When presenting, a first-use patient&#x000a0;is not in acute distress (barring active trauma or chronic pain) or has physical withdrawal signs. The tolerant patient will typically present with a story that necessitates increasing the dose of medication or an unexpected refill. The patient with full addiction can present in acute withdrawal with symptoms that vary based on the substance. Alcohol withdrawal will present with signs of autonomic dysregulation to the most worrisome, delirium tremens and seizures.<xref ref-type="bibr" rid="article-17181.r27">[27]</xref></p>
      </sec>
      <sec id="article-17181.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Lab values (blood and urine), imaging, and specific tests vary depending on the cause of the addiction. If it is a psychoactive substance, there may be apparent derangements in&#x000a0;the comprehensive metabolic panel (CMP) and complete blood count (CBC) values, as well as in the psychoanalysis and behavioral screening. The following is an abbreviated list of commonly used substances:</p>
        <list list-type="order">
          <list-item>
            <p>Alcohol
<list list-type="order"><list-item><p>CBC &#x02013; Chronic use can cause an elevated mean corpuscular volume (MCV) with megaloblastic anemia from folate deficiency.<xref ref-type="bibr" rid="article-17181.r28">[28]</xref></p></list-item><list-item><p>CMP &#x02013; Blood urea nitrogen/creatinine ratio (BUN/Cr) may be above baseline, glucose may be chronically low, and electrolytes may be deranged from dehydration.
<list list-type="order"><list-item><p>The anion gap&#x000a0;is elevated in acute intoxication with a decreased CO<sub>2</sub> and decreased bicarbonate, reflecting an acidotic state.</p></list-item></list>
</p></list-item><list-item><p>Methanol&#x000a0;is the same with an addition of ophthalmologic issues.<xref ref-type="bibr" rid="article-17181.r29">[29]</xref> It requires regular and serial eye examinations in the emergency department.</p></list-item><list-item><p>Ethylene glycol leads to renal failure, necessitating serial BUN/Cr levels and GFR to monitor renal function; oxalic acid kidney stones commonly result in bloody urine on urinalysis (UA).</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Cocaine: An apparent sympathetic drive is expressed through elevated vitals. Patients are typically tachycardic and tachypneic. In addition, patients may present with acute psychosis. Intoxications may necessitate serial troponins, cardiac stress tests, and cardiac catheterization.<xref ref-type="bibr" rid="article-17181.r30">[30]</xref> Due to the vasoconstriction of coronary vessels, troponins&#x000a0;are regularly elevated.</p>
          </list-item>
          <list-item>
            <p>Opioids: Opposite to stimulants like cocaine, opioids present with parasympathetic symptoms such as bradycardia, hypotension, miosis, hypothermia, and sedation. The worrisome factor is sedation, leading to respiratory depression.</p>
          </list-item>
        </list>
        <p>Please refer to the clinical pearls section for detailed screening criteria, such as CAGE, AUDIT, and the CIWA criteria.</p>
        <p>An evaluation commonly used for addiction screening is the Addiction Severity Index (ASI). The screening evaluates&#x000a0;7 domains:</p>
        <list list-type="order">
          <list-item>
            <p>Medical status</p>
          </list-item>
          <list-item>
            <p>Employment and support</p>
          </list-item>
          <list-item>
            <p>Drug use</p>
          </list-item>
          <list-item>
            <p>Alcohol use</p>
          </list-item>
          <list-item>
            <p>Legal status</p>
          </list-item>
          <list-item>
            <p>Family/social status</p>
          </list-item>
          <list-item>
            <p>Psychiatric status</p>
          </list-item>
        </list>
        <p>The screening does not cover all special populations, such as the homeless; it is extensively cross-reviewed to show significant reliability and validity as the foundation of treatment plans for patients with addiction.<xref ref-type="bibr" rid="article-17181.r31">[31]</xref></p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Although not routine in clinical practice, imaging may be integrated into the evaluation panel of addiction. Researchers found that reduced dopamine (DA D2) receptors correlated with decreased activity in the anterior cingulate gyrus and orbitofrontal cortex in detoxified cocaine abusers.<xref ref-type="bibr" rid="article-17181.r32">[32]</xref></p>
        <p>
<bold>Liquid Chromatography, Mass Spectrometry, and&#x000a0;Ion Mobility Spectrometry</bold>
</p>
        <p>Some substances, such as kratom and bath salts, are unidentifiable on a regular urine drug screen or blood work. Techniques such as liquid chromatography, mass spectrometry, and ion mobility spectrometry (IMS) are helpful.<xref ref-type="bibr" rid="article-17181.r21">[21]</xref></p>
      </sec>
      <sec id="article-17181.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Intoxications go hand-in-hand with addictions as they can either be the subject of the addiction or the propelling factor toward behavioral disruptions and suicidal tendencies. Further management involves monitoring and maintaining the patient's vital signs. This is dependent on the stage of presentation of the patient and the subject of the addiction. Multiple pharmacological treatments are available for the&#x000a0;2 most common substance addictions (tobacco and alcohol), such as group meetings and psychological and social support.</p>
        <p>Pharmacologically, alcohol dependence is treatable with disulfiram, naltrexone, and acamprosate.<xref ref-type="bibr" rid="article-17181.r33">[33]</xref>&#x000a0;Each has its place in alcohol dependence and addiction. Disulfiram is effective in managing a patient who recently quit and needs help maintaining abstinence, as any consumed alcohol causes relatively quick hangover-type symptoms to deter further drinking. Naltrexone removes the sensation of reward or pleasure with drinking, and acamprosate minimizes the initial withdrawal symptoms. Alcohol intoxication during episodes of relapse is treatable with long-acting benzodiazepines such as chlordiazepoxide or diazepam.<xref ref-type="bibr" rid="article-17181.r34">[34]</xref></p>
        <p>For tobacco dependence, there is currently bupropion and varenicline.&#x000a0;Off-label uses exist for drugs like clonidine, an alpha-2 agonist for managing high blood pressure. Also, there is nortriptyline, a member of the TCA class of antidepressants. Both of the latter drugs are effective if started before quitting. As for bupropion, the pill cuts down the craving for tobacco.<xref ref-type="bibr" rid="article-17181.r35">[35]</xref> Varenicline helps curb the craving for nicotine as well as decrease withdrawal symptoms.<xref ref-type="bibr" rid="article-17181.r35">[35]</xref> Along with these options are nicotine patches, gums, sprays, and lozenges.</p>
        <p>Ultimately, however, these pharmacological interventions&#x000a0;are combined with non-pharmacological methods for optimal efficacy and to limit and prevent substance use from developing into misuse to dependence. For example, regarding nicotine dependence, pharmacological treatments employed with the&#x000a0;clinician's advice and empathy result in approximately double the long-term abstinence.<xref ref-type="bibr" rid="article-17181.r35">[35]</xref></p>
        <p>Of interest, more people have overcome their addiction than those enrolled in a program (eg, 12-step, CBT).<xref ref-type="bibr" rid="article-17181.r36">[36]</xref> For these reasons, consideration is necessary to treat an individual with addiction or not. If one plans to initiate treatment, a joint plan involving the patient's input yields better results.</p>
      </sec>
      <sec id="article-17181.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In terms of addictions, the differential should include ruling out the root causes of the addiction. Potential root causes are as follows:</p>
        <p>Bipolar disorder &#x02013; more than half of patients with substance abuse disorder have bipolar disorder, and significant mood fluctuations can present in the patient.<xref ref-type="bibr" rid="article-17181.r37">[37]</xref></p>
        <p>Post-traumatic stress disorder (PTSD) &#x02013; common concurrence among alcohol abusers. PTSD should be screened in all addicts. While the&#x000a0;2 are different conditions with separate signs and symptoms, treating the cause of PTSD can mitigate or eliminate the underlying addiction.</p>
        <p>Since most cases of intoxication involve episodes of altered mental status, a helpful mnemonic for the emergency department physician is the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>A</bold> - alcohol</p>
          </list-item>
          <list-item>
            <p><bold>E</bold> &#x02013; encephalopathy (hypertensive, hepatic), electrolytes, endocrine, environmental</p>
          </list-item>
          <list-item>
            <p><bold>I</bold> &#x02013; insulin</p>
          </list-item>
          <list-item>
            <p><bold>O</bold> &#x02013; opiates, oxygen</p>
          </list-item>
          <list-item>
            <p><bold>U</bold> &#x02013; uremia</p>
          </list-item>
          <list-item>
            <p><bold>T</bold> &#x02013; trauma, toxins</p>
          </list-item>
          <list-item>
            <p><bold>I</bold> &#x02013; infection, increased intracranial pressure</p>
          </list-item>
          <list-item>
            <p><bold>P</bold> &#x02013; psychosis, poisoning, porphyria</p>
          </list-item>
          <list-item>
            <p><bold>S</bold> &#x02013; stroke, shock, seizure</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17181.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Stages of addiction: refer above to the history and physical discussion to review the steps of addiction.</p>
        <p>Stages of recovery and change from addiction include:</p>
        <list list-type="order">
          <list-item>
            <p>Precontemplation: the patient still has yet to acknowledge the problem</p>
          </list-item>
          <list-item>
            <p>Contemplation: the patient has recognized the problem but not yet dealing with it</p>
          </list-item>
          <list-item>
            <p>Preparation: the patient makes an appointment to discuss receiving help</p>
          </list-item>
          <list-item>
            <p>Action: the patient begins treatment to reach and maintain abstinence</p>
          </list-item>
          <list-item>
            <p>Maintenance: the patient has become abstinent and is maintaining positive coping strategies</p>
          </list-item>
          <list-item>
            <p>Relapse: during the maintenance phase, patients may fall into the relapse stage from time to time and restart the recovery process&#x000a0;<xref ref-type="bibr" rid="article-17181.r38">[38]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17181.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The evidence is quite clear on the long-term effects of drug dependence, with those diagnosed dying 22.5 years earlier than those without the diagnosis.&#x000a0;This lifespan is related to the toxic effects of substances on multiple systems, including, but not limited to, the cardiac, respiratory, and neurological systems. Also, a 5-year study on alcohol and drug rehabilitation treatment found that older adults have favorable long-term outcomes versus young adults, especially older women, who had 52% 30-day abstinence rates versus a 40% younger adult rate.<xref ref-type="bibr" rid="article-17181.r39">[39]</xref><xref ref-type="bibr" rid="article-17181.r40">[40]</xref> Factors such as social networks and gender play a role alongside age in these numbers.</p>
        <p>Based on the current research on addiction, practitioners need to shift the management of patients from an acute paradigm to a chronic disease paradigm.<xref ref-type="bibr" rid="article-17181.r39">[39]</xref> Furthermore, we must bolster the condition's screening, intervention, and overall management. Urgency is necessary for this shift as 6.9 million, or 2.8% of the US population, have the mortality risk associated with illicit drug use.<xref ref-type="bibr" rid="article-17181.r39">[39]</xref> However, before any change gains traction, current research must bolster the evidence of decreased mortality with decreases in the prevalence and incidence of addiction.</p>
        <p>Currently, there is a clear relationship between the changes in mortality risk and when patients begin treatment.<xref ref-type="bibr" rid="article-17181.r39">[39]</xref> The prognosis depends on these factors.</p>
      </sec>
      <sec id="article-17181.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Regarding chronic alcohol use, Wernicke encephalopathy and Korsakoff syndrome&#x000a0;are expected complications.&#x000a0;The Wernicke encephalopathy&#x000a0;consists&#x000a0;of the triad of confusion, ophthalmoplegia, and ataxia (though usually, only one is present 20% of the time).<xref ref-type="bibr" rid="article-17181.r41">[41]</xref>&#x000a0;Classic findings on CT and MRI scanning include atrophy of the bilateral mammillary bodies and hippocampal areas.<xref ref-type="bibr" rid="article-17181.r41">[41]</xref></p>
        <p>Hepatic steatosis is a common complication of chronic alcohol use that results from cholesterol esters, phospholipids, and triglycerides formed ultimately from alcohol-induced ROS formation, altering lipid metabolism. Chronic heavy alcohol consumption is the most critical risk factor for chronic pancreatitis. The process begins with acute heavy consumption, which, through the toxic effects of alcohol metabolism, induces inflammatory and fibrotic changes in the pancreas over time. Specifically, the pancreatic stellate cells&#x000a0;are activated, resulting in the expected fibrotic changes.</p>
        <p>Cardiomyopathy is another documented complication expected due to chronic alcohol use resulting from oxidative stress, disruptions in proper calcium handling, and mitochondrial dysfunction.<xref ref-type="bibr" rid="article-17181.r42">[42]</xref>&#x000a0;Cocaine addiction and intoxication lead to myocardial ischemia, psychosis, and fatal arrhythmias that require acute management to mitigate effects.<xref ref-type="bibr" rid="article-17181.r43">[43]</xref>&#x000a0;From a behavioral perspective, addiction leads to multiple episodes of withdrawal and relapses.</p>
      </sec>
      <sec id="article-17181.s14" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Rehabilitation treatment&#x000a0;is the cornerstone of managing a patient with addiction, from sobering to maintaining their remission. Since the 1960s, various public and private modalities have been founded, such as methadone clinics, free outpatient treatment programs, and residential community treatment sites.<xref ref-type="bibr" rid="article-17181.r44">[44]</xref></p>
        <p>Among the most common and effective programs are the 12-step programs, including Alcoholics Anonymous (AA), Narcotics Anonymous, and Cocaine Anonymous. These peer support groups are commonplace in addiction management with the dual benefit of aiding drug addiction reform and co-occurring mental health problems. Some of the positive outcomes of these programs include increased self-confidence, self-efficacy, and healthy coping strategies for addicts to maintain their abstinence. Overall, rehabilitation care for addiction management includes fail-safes that prevent relapse through pharmacological deterrents and peer-support groups.<xref ref-type="bibr" rid="article-17181.r45">[45]</xref></p>
      </sec>
      <sec id="article-17181.s15" sec-type="Consultations">
        <title>Consultations</title>
        <p>Psychiatry consults are necessary as addiction stems from underlying behavioral or psychological issues. However, due to the many medical or surgical complications associated with addiction, medical, surgical, or trauma consults&#x000a0;are necessary. In addition, these consultations are required to address impending death due to complications, such as myocardial infarction, acute kidney failure, rhabdomyolysis, etc associated with stimulants like cocaine and amphetamine.</p>
      </sec>
      <sec id="article-17181.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence depends on proper screening criteria for early signs of potential addiction and early childhood education. School programs like DARE represent a positive effort to curb drug use and experimentation. However, while&#x000a0;education is most effective before the development of health problems, patient education has a place at any stage of addiction. Patients are more likely to reach and maintain abstinence and institute positive lifestyle changes if&#x000a0;clinicians and other healthcare professionals engage in consistent and positive patient encouragement.</p>
      </sec>
      <sec id="article-17181.s17" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Moderate alcohol consumption is defined as one drink per day for women and up to 2 drinks per day for men. Studies have revealed that this low to moderate alcohol use has been demonstrated to lower the risk of coronary artery disease.</p>
        <p>The average rate of alcohol metabolism is approximately 7 grams per hour, equal to 1 drink per hour.</p>
        <p>The CAGE questionnaire for alcoholism screening is as follows:</p>
        <list list-type="order">
          <list-item>
            <p>Have you ever felt the need to&#x000a0;cut down on your drinking?</p>
          </list-item>
          <list-item>
            <p>Have people&#x000a0;annoyed you by criticizing your drinking?</p>
          </list-item>
          <list-item>
            <p>Have you ever felt&#x000a0;guilty drinking?</p>
          </list-item>
          <list-item>
            <p>Have you ever felt you needed a drink first thing in the morning (eyeopener) to steady your nerves or to get rid of a hangover?<xref ref-type="bibr" rid="article-17181.r46">[46]</xref></p>
          </list-item>
        </list>
        <p>Each yes gets a +1, and each no gets a 0 for a total of 4. However, CAGE falls short in lower-severity situations. For these (if provided with ample time for interviewing), refer to the alcohol use disorders identification test (AUDIT):</p>
        <list list-type="order">
          <list-item>
            <p>How often have you had a drink containing alcohol this past year?</p>
          </list-item>
          <list-item>
            <p>How many drinks of alcohol did you have on a typical day you were drinking this past year?</p>
          </list-item>
          <list-item>
            <p>How often did you have&#x000a0;6 or more drinks on one occasion this past year?<xref ref-type="bibr" rid="article-17181.r47">[47]</xref></p>
          </list-item>
        </list>
        <p>Each question has&#x000a0;4 potential categories for responses, allowing each category a maximum of 4 and a low of 0. Scores less than 3 are consistent with normal alcohol consumption.</p>
        <p>
<bold>CIWA Criteria</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Nausea or vomiting 0-7</p>
          </list-item>
          <list-item>
            <p>Tremor 0-7</p>
          </list-item>
          <list-item>
            <p>Paroxysmal sweats 0-7</p>
          </list-item>
          <list-item>
            <p>Anxiety 0-7</p>
          </list-item>
          <list-item>
            <p>Agitation 0-7</p>
          </list-item>
          <list-item>
            <p>Tactile disturbances 0-7</p>
          </list-item>
          <list-item>
            <p>Auditory disturbances 0-7</p>
          </list-item>
          <list-item>
            <p>Visual disturbances 0-7</p>
          </list-item>
          <list-item>
            <p>Headache or fullness in the head 0-7</p>
          </list-item>
          <list-item>
            <p>Orientation or clouding of sensorium 0-4</p>
          </list-item>
        </list>
        <p>Patients less than or equal to a score of 8 do not require medical treatment, whereas those above do.</p>
        <p>While patients addicted to opioids may develop a tolerance for all other side effects, constipation, and miosis remain constant&#x000a0;after the dosage. Therefore, providers should screen patients with these side effects before signs and symptoms of respiratory depression.</p>
        <p>Although variable among the states, typical BAC levels that define alcohol intoxication are 80 mg/dL to 100 mg/dL (.08% to 0.1% BAC). For the chronic user, these levels take more time. In addition, one should avoid bupropion in patients with a current or past history of eating disorders, as this lowers&#x000a0;the threshold for seizure side effects.</p>
      </sec>
      <sec id="article-17181.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Addiction is a very complex condition with multiple episodes of reaching abstinence and falling into relapse; this is why an interprofessional team is vital in treatment. Treatment begins with the&#x000a0;clinician's&#x000a0;risk factor identification and diagnosis but quickly grows to involve interprofessional teams to help the patient maintain abstinence. Through thorough evaluation, primary care&#x000a0;clinicians&#x000a0;can screen patients using the abovementioned criteria. These patients should have regular follow-up care. At the same time, social and familial support can be called upon to prevent the progression of addiction.</p>
        <p>Once diagnosed, the swift involvement of a psychiatrist and dietician is essential. The psychiatrist can help uncover the root causes of the addiction, while the dietician can help maintain the patient's overall health.&#x000a0;</p>
        <p>During relapses, nurses play pivotal roles. They can help track patient vitals, and proper medication and fluids are provided promptly to manage acute intoxications and aid the patient towards abstinence. Pharmacists are also essential members of the interprofessional team. They may be the first to notice addictive behaviors if the addiction involves prescription drugs. They are also good resources for detoxification, assisting clinicians in treatment and rehab centers, verifying dosing, and checking for drug interactions.</p>
        <p>Also discussed above, 12-step programs, such as Alcoholics Anonymous, involving peer support, are integral to developing and maintaining abstinence.<xref ref-type="bibr" rid="article-17181.r48">[48]</xref> Primary care clinicians, emergency department clinicians, nurses, 12-step programs, dieticians, and psychiatrists have well-researched roles in diagnosing and managing addiction patients. The interprofessional team of clinicians, nurses, specialists, psychological professionals, pharmacists, dieticians, and social workers must all coordinate their actions to achieve the best patient outcomes for addiction disorders.&#x000a0;</p>
      </sec>
      <sec id="article-17181.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17181&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17181">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/addiction/drug-addiction/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17181">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17181/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17181">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17181.s20">
        <title>References</title>
        <ref id="article-17181.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kranzler</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>What is addiction?</article-title>
            <source>Alcohol Res Health</source>
            <year>2008</year>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-5</page-range>
            <pub-id pub-id-type="pmid">23584810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grant</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Potenza</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Introduction to behavioral addictions.</article-title>
            <source>Am J Drug Alcohol Abuse</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>233</fpage>
            <page-range>233-41</page-range>
            <pub-id pub-id-type="pmid">20560821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaffer</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>LaPlante</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>LaBrie</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kidman</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Toward a syndrome model of addiction: multiple expressions, common etiology.</article-title>
            <source>Harv Rev Psychiatry</source>
            <year>2004</year>
            <season>Nov-Dec</season>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>367</fpage>
            <page-range>367-74</page-range>
            <pub-id pub-id-type="pmid">15764471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blum</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oscar-Berman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demetrovics</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Barh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).</article-title>
            <source>Mol Neurobiol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>765</fpage>
            <page-range>765-96</page-range>
            <pub-id pub-id-type="pmid">24878765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koob</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Le Moal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug addiction, dysregulation of reward, and allostasis.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-129</page-range>
            <pub-id pub-id-type="pmid">11120394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nestler</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Barrot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>DeltaFosB: a sustained molecular switch for addiction.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2001</year>
            <month>Sep</month>
            <day>25</day>
            <volume>98</volume>
            <issue>20</issue>
            <fpage>11042</fpage>
            <page-range>11042-6</page-range>
            <pub-id pub-id-type="pmid">11572966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perrotti</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Hadeishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ulery</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Barrot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Monteggia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Nestler</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Induction of deltaFosB in reward-related brain structures after chronic stress.</article-title>
            <source>J Neurosci</source>
            <year>2004</year>
            <month>Nov</month>
            <day>24</day>
            <volume>24</volume>
            <issue>47</issue>
            <fpage>10594</fpage>
            <page-range>10594-602</page-range>
            <pub-id pub-id-type="pmid">15564575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Chronic stress, drug use, and vulnerability to addiction.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>1141</volume>
            <fpage>105</fpage>
            <page-range>105-30</page-range>
            <pub-id pub-id-type="pmid">18991954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres-Berrio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cuesta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lopez-Guzman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nava-Mesa</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>Interaction Between Stress and Addiction: Contributions From Latin-American Neuroscience.</article-title>
            <source>Front Psychol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>2639</fpage>
            <pub-id pub-id-type="pmid">30622500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harford</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Patterns of DSM-IV alcohol abuse and dependence criteria among adolescents and adults: results from the 2001 National Household Survey on Drug Abuse.</article-title>
            <source>Alcohol Clin Exp Res</source>
            <year>2005</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>810</fpage>
            <page-range>810-28</page-range>
            <pub-id pub-id-type="pmid">15897727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>GBD 2016 Alcohol and Drug Use Collaborators</collab>
            <article-title>The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>987</fpage>
            <page-range>987-1012</page-range>
            <pub-id pub-id-type="pmid">30392731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weaver</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Hopper</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gunderson</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <article-title>Designer drugs 2015: assessment and management.</article-title>
            <source>Addict Sci Clin Pract</source>
            <year>2015</year>
            <month>Mar</month>
            <day>25</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <pub-id pub-id-type="pmid">25928069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solimini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pichini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pacifici</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Busard&#x000f2;</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Giorgetti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>654</fpage>
            <pub-id pub-id-type="pmid">29973882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christophersen</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Amphetamine designer drugs - an overview and epidemiology.</article-title>
            <source>Toxicol Lett</source>
            <year>2000</year>
            <month>Mar</month>
            <day>15</day>
            <volume>112-113</volume>
            <fpage>127</fpage>
            <page-range>127-31</page-range>
            <pub-id pub-id-type="pmid">10720721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Suerken</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Reboussin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Spangler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wagoner</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Sutfin</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Debinski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wolfson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>K2 and Spice use among a cohort of college students in southeast region of the USA.</article-title>
            <source>Am J Drug Alcohol Abuse</source>
            <year>2015</year>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-22</page-range>
            <pub-id pub-id-type="pmid">26030768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cottencin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rolland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karila</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature.</article-title>
            <source>Curr Pharm Des</source>
            <year>2014</year>
            <volume>20</volume>
            <issue>25</issue>
            <fpage>4106</fpage>
            <page-range>4106-11</page-range>
            <pub-id pub-id-type="pmid">24001292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lovrecic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lovrecic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gabrovec</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maremmani</surname>
                <given-names>AGI</given-names>
              </name>
              <name>
                <surname>Maremmani</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2019</year>
            <month>Jan</month>
            <day>09</day>
            <volume>16</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30634521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shoff</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Zaney</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hime</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Qualitative Identification of Fentanyl Analogs and Other Opioids in Postmortem Cases by UHPLC-Ion Trap-MSn.</article-title>
            <source>J Anal Toxicol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>484</fpage>
            <page-range>484-492</page-range>
            <pub-id pub-id-type="pmid">28633314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rattana</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Quock</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Prescription opioid abuse: a literature review of the clinical and economic burden in the United States.</article-title>
            <source>Popul Health Manag</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>372</fpage>
            <page-range>372-87</page-range>
            <pub-id pub-id-type="pmid">25075734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbott</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Use and abuse of over-the-counter analgesic agents.</article-title>
            <source>J Psychiatry Neurosci</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-34</page-range>
            <pub-id pub-id-type="pmid">9505057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fluyau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Revadigar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom.</article-title>
            <source>Front Psychiatry</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>62</fpage>
            <pub-id pub-id-type="pmid">28484399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gould</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Addiction and cognition.</article-title>
            <source>Addict Sci Clin Pract</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>4</fpage>
            <page-range>4-14</page-range>
            <pub-id pub-id-type="pmid">22002448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shippenberg</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Zapata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chefer</surname>
                <given-names>VI</given-names>
              </name>
            </person-group>
            <article-title>Dynorphin and the pathophysiology of drug addiction.</article-title>
            <source>Pharmacol Ther</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>116</volume>
            <issue>2</issue>
            <fpage>306</fpage>
            <page-range>306-21</page-range>
            <pub-id pub-id-type="pmid">17868902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volkow</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>The addicted human brain: insights from imaging studies.</article-title>
            <source>J Clin Invest</source>
            <year>2003</year>
            <month>May</month>
            <volume>111</volume>
            <issue>10</issue>
            <fpage>1444</fpage>
            <page-range>1444-51</page-range>
            <pub-id pub-id-type="pmid">12750391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molina</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Souza-Smith</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Alcohol abuse: critical pathophysiological processes and contribution to disease burden.</article-title>
            <source>Physiology (Bethesda)</source>
            <year>2014</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-15</page-range>
            <pub-id pub-id-type="pmid">24789985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brady</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Lydiard</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Malcolm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ballenger</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Cocaine-induced psychosis.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>12</issue>
            <fpage>509</fpage>
            <page-range>509-12</page-range>
            <pub-id pub-id-type="pmid">1752853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mainerova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prasko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Latalova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Axmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cerna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horacek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bradacova</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Alcohol withdrawal delirium - diagnosis, course and treatment.</article-title>
            <source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-52</page-range>
            <pub-id pub-id-type="pmid">24399242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindenbaum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Nutritional anemia in alcoholism.</article-title>
            <source>Am J Clin Nutr</source>
            <year>1980</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>2727</fpage>
            <page-range>2727-35</page-range>
            <pub-id pub-id-type="pmid">7001890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mojica</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Pasol</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Dizon</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kiat</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>TRU</given-names>
              </name>
              <name>
                <surname>Dominguez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Valencia</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Tua&#x000f1;o</surname>
                <given-names>BJP</given-names>
              </name>
            </person-group>
            <article-title>Chronic methanol toxicity through topical and inhalational routes presenting as vision loss and restricted diffusion of the optic nerves on MRI: A case report and literature review.</article-title>
            <source>eNeurologicalSci</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>20</volume>
            <fpage>100258</fpage>
            <pub-id pub-id-type="pmid">32775706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kontos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Tatum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jesse</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Utility of troponin I in patients with cocaine-associated chest pain.</article-title>
            <source>Acad Emerg Med</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>1007</fpage>
            <page-range>1007-13</page-range>
            <pub-id pub-id-type="pmid">12359538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waxman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hatzenbuehler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hasin</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Assessing addiction: concepts and instruments.</article-title>
            <source>Addict Sci Clin Pract</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-31</page-range>
            <pub-id pub-id-type="pmid">18292706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volkow</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>RZ</given-names>
              </name>
            </person-group>
            <article-title>Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies.</article-title>
            <source>Neurobiol Learn Mem</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>610</fpage>
            <page-range>610-24</page-range>
            <pub-id pub-id-type="pmid">12559839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>T&#x000f8;nnesen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of disulfiram for the treatment of alcohol use disorder.</article-title>
            <source>Alcohol Clin Exp Res</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>1749</fpage>
            <page-range>1749-58</page-range>
            <pub-id pub-id-type="pmid">21615426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gatch</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment of alcoholism.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>917</fpage>
            <page-range>917-44</page-range>
            <pub-id pub-id-type="pmid">9789878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aubin</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Luquiens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>324</fpage>
            <page-range>324-36</page-range>
            <pub-id pub-id-type="pmid">23488726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peele</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>What works in addiction treatment and what doesn't: is the best therapy no therapy?</article-title>
            <source>Int J Addict</source>
            <string-date>1990-1991</string-date>
            <volume>25</volume>
            <issue>12A</issue>
            <fpage>1409</fpage>
            <page-range>1409-19</page-range>
            <pub-id pub-id-type="pmid">1966834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Post</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kalivas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation.</article-title>
            <source>Br J Psychiatry</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>202</volume>
            <issue>3</issue>
            <fpage>172</fpage>
            <page-range>172-6</page-range>
            <pub-id pub-id-type="pmid">23457180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacey</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Street</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Measuring healthy behaviours using the stages of change model: an investigation into the physical activity and nutrition behaviours of Australian miners.</article-title>
            <source>Biopsychosoc Med</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">29213300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Laudet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Funk</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Simeone</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Surviving drug addiction: the effect of treatment and abstinence on mortality.</article-title>
            <source>Am J Public Health</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>101</volume>
            <issue>4</issue>
            <fpage>737</fpage>
            <page-range>737-44</page-range>
            <pub-id pub-id-type="pmid">21330586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satre</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Are&#x000e1;n</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Weisner</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Five-year alcohol and drug treatment outcomes of older adults versus middle-aged and younger adults in a managed care program.</article-title>
            <source>Addiction</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>99</volume>
            <issue>10</issue>
            <fpage>1286</fpage>
            <page-range>1286-97</page-range>
            <pub-id pub-id-type="pmid">15369567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Macaluso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Empaire</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Wernicke's Encephalopathy: Increasing Clinician Awareness of This Serious, Enigmatic, Yet Treatable Disease.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2015</year>
            <volume>17</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">26644959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehm</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The risks associated with alcohol use and alcoholism.</article-title>
            <source>Alcohol Res Health</source>
            <year>2011</year>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-43</page-range>
            <pub-id pub-id-type="pmid">22330211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karila</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Coscas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benyamina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reynaud</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Complications of cocaine addiction].</article-title>
            <source>Rev Prat</source>
            <year>2009</year>
            <month>Jun</month>
            <day>20</day>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>825</fpage>
            <page-range>825-9</page-range>
            <pub-id pub-id-type="pmid">19642439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quinones</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Sheffet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Louria</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of drug abuse rehabilitation efforts: a review.</article-title>
            <source>Am J Public Health</source>
            <year>1979</year>
            <month>Nov</month>
            <volume>69</volume>
            <issue>11</issue>
            <fpage>1164</fpage>
            <page-range>1164-9</page-range>
            <pub-id pub-id-type="pmid">507249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tracy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Benefits of peer support groups in the treatment of addiction.</article-title>
            <source>Subst Abuse Rehabil</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>143</fpage>
            <page-range>143-154</page-range>
            <pub-id pub-id-type="pmid">27729825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhalla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kopec</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies.</article-title>
            <source>Clin Invest Med</source>
            <year>2007</year>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-41</page-range>
            <pub-id pub-id-type="pmid">17716538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gache</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Accietto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arfaoui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Daeppen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>The Alcohol Use Disorders Identification Test (AUDIT) as a screening tool for excessive drinking in primary care: reliability and validity of a French version.</article-title>
            <source>Alcohol Clin Exp Res</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>2001</fpage>
            <page-range>2001-7</page-range>
            <pub-id pub-id-type="pmid">16340457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17181.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Alcoholics Anonymous and other 12-step programs for alcohol use disorder.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Mar</month>
            <day>11</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD012880</fpage>
            <pub-id pub-id-type="pmid">32159228</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
